Aurobindo Pharma Limited

NSE:AUROPHARMA.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

🔬 Clinical Trials

Location

India

Market Cap

USD 7.36 B

Share Price

USD 12.66

Avg Daily Volume

1,293,153

Change (1 day)

1.46%

Change (1 year)

-14.76%

Change (YTD)

-18.76%

Aurobindo Pharma Limited Share Price Year-To-Date (YTD) return on June 20, 2025: -18.76%

Aurobindo Pharma Limited Share Price Year-To-Date (YTD) return is -18.76% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Aurobindo Pharma Limited 52-week low Share Price is USD 18.71 on June 20, 2025, which is 47.70% above the current Share Price.
Aurobindo Pharma Limited 52-week low Share Price is USD 12.06 on June 20, 2025, which is -4.81% below the current Share Price.
Aurobindo Pharma Limited average Share Price for the last 52 weeks is USD 15.12.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NSE: AUROPHARMA.NS

Aurobindo Pharma Limited

CEO	Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
IPO Date	Jan. 15, 1996
Location	India
Headquarters	Galaxy, Plot No. 1
Employees	26,015
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Chemicals & Advanced Materials 🔬 Clinical Trials

Description

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.